TriSalus Life Sciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $45.2M | $29.4M | $18.5M | $12.4M | — |
| Cost of revenue | $7.0M | $4.1M | $2.6M | $2.3M | — |
| Gross profit | $38.2M | $25.3M | $15.9M | $10.1M | — |
| Research and development | $15.0M | $17.7M | $29.8M | $21.4M | — |
| Operating income | -$26.9M | -$36.2M | -$54.5M | -$36.4M | -$3.0M |
| Interest expense | $5.5M | $3.1M | $16,000 | $1,000 | — |
| Pretax income | -$39.2M | -$30.0M | -$59.4M | -$47.2M | $4.8M |
| Income tax expense | $7,000 | $6,000 | $9,000 | $9,000 | $0 |
| Net income | -$39.2M | -$30.0M | -$59.4M | -$47.2M | $4.8M |
| Balance Sheet | |||||
| Cash and equivalents | $20.4M | $8.5M | $11.8M | $9.4M | $200,884 |
| Current assets | $32.2M | $20.7M | $20.9M | $17.2M | $525,884 |
| Total assets | $35.3M | $24.0M | $24.6M | $22.0M | $250.5M |
| Current liabilities | $11.5M | $10.2M | $14.7M | $32.4M | $1.6M |
| Total liabilities | $69.2M | $49.9M | $51.7M | $34.3M | $17.3M |
| Stockholders' equity | -$33.9M | -$25.9M | -$27.1M | -$177.1M | -$129.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$18.0M | -$40.8M | -$50.6M | -$32.3M | -$1.7M |
| Depreciation and amortization | $600,000 | $700,000 | $700,000 | $276,000 | — |
| Stock-based compensation | $9.1M | $5.4M | $1.4M | $368,000 | — |
| Capital expenditure | $918,000 | $345,000 | $588,000 | $655,000 | — |
| Free cash flow | -$18.9M | -$41.2M | -$51.2M | -$33.0M | — |
| Share repurchases | — | — | — | $232.4M | — |
Shares outstanding 61.4M · Free float 45.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.